All lobbying filings

MARSHALL & POPP, LLC

Lobbying for JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES · Pharmaceuticals.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $40,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 3

HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
S 2256
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
HR 946
ORPHAN Cures Act

Lobbying activity 1

Health Issues

Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.